New Guideline Recommends CYP2C19 Genotyping Before Clopidogrel Therapy
Lydia Kariuki, Managing Editor at American Pharmacogenomics Association, posted on LinkedIn:
“CYP2C19 pharmacogenetic (PGx) testing for all patients in the UK before prescribing clopidogrel
The UK has taken a major step forward in precision prescribing with the publication of its first national pharmacogenomic guideline, focused on the antiplatelet drug clopidogrel.
Clopidogrel is widely prescribed across the NHS to prevent blood clots in patients with coronary artery disease, cerebrovascular disease, and peripheral arterial disease. But while the medication is standard therapy, its effectiveness varies substantially between individuals. The new guideline directly addresses this variability by recommending CYP2C19 genotyping for patients before clopidogrel therapy is initiated.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Apr 8, 2026, 15:21Nathan Connell: Persistent Gaps in Hemophilia A Care Despite Prophylaxis
-
Apr 8, 2026, 15:16Avril Mansfield: Why Aren’t More Stroke Patients Meeting Aerobic Exercise Guidelines?
-
Apr 8, 2026, 15:06Sarah Richardson: We Need Experts, We Need Programs and We Need Accountability in Blood Disorders Community
-
Apr 8, 2026, 15:02Heghine Khachatryan: When Bleeding Appears Without a History — Think Acquired
-
Apr 8, 2026, 14:58Nominate a Bleeding Disorders Community Hero Making a Difference – NBDF
-
Apr 8, 2026, 14:56Joffrey Feriel: Comprehensive Review of Laboratory Assays for von Willebrand Factor and Associated Disorders
-
Apr 8, 2026, 14:54Husnain Ahmad: How Aortic Stenosis Can Lead to Gastrointestinal Bleeding in Heyde Syndrome
-
Apr 8, 2026, 14:51Steven Murphy: How Much Benefit Do Statins Really Provide for Cardiovascular Prevention
-
Apr 8, 2026, 14:42Joshua Muia: The Value of Collaboration and The Importance of Exchanging Ideas Across Institutions